STALICLA SA
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 2017-05-01
- Employees
- 11
- Market Cap
- -
- Website
- http://stalicla.com
Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase1, STP7 Cocaine Drug-Drug Interaction Study
- Conditions
- Cocaine Use Disorder
- Interventions
- Drug: STP7 (mavoglurant) or Placebo
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Stalicla SA
- Target Recruit Count
- 21
- Registration Number
- NCT06273540
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Overland Park, Kansas, United States
International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder
- Conditions
- Autism Spectrum Disorder
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Stalicla SA
- Target Recruit Count
- 1500
- Registration Number
- NCT05590715
- Locations
- 🇺🇸
SARRC, Phoenix, Arizona, United States
🇺🇸California Neuroscience Research, Sherman Oaks, California, United States
🇺🇸The Angel Medical Research, Miami Lakes, Florida, United States
Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder (ASD)
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Stalicla SA
- Target Recruit Count
- 12
- Registration Number
- NCT04644003
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Characterization of a Clinical Subpopulation in Children With Autism Spectrum Disorder
- Conditions
- Autism Spectrum Disorder
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Stalicla SA
- Registration Number
- NCT04600882
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
Characterization of a Clinical Subpopulation With Autism Spectrum Disorder
- Conditions
- Autism Spectrum Disorder
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Stalicla SA
- Target Recruit Count
- 236
- Registration Number
- NCT04273087
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
News
Stalicla Secures CHF 2 Million Financing from Addex Therapeutics to Advance Precision Medicine for Autism and Neurodevelopmental Disorders
Geneva-based Stalicla SA closed a CHF 2 million financing round led by Addex Therapeutics to sustain operations and advance its precision medicine programs for neurodevelopmental disorders.